




PHARMACEUTICAL 2023

HERON THERAPEUTICS INC. DE Rank 347 of 446





PHARMACEUTICAL 2023

HERON THERAPEUTICS INC. DE Rank 347 of 446



The relative strengths and weaknesses of HERON THERAPEUTICS INC. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HERON THERAPEUTICS INC. DE compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 24% points. The greatest weakness of HERON THERAPEUTICS INC. DE is the variable Other Liabilities, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 108% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	205,435
Cost of Goods Sold	54,874
Intangible Assets	0
Liabilities, Current	82,355
Liabilities, Non-Current	5,740
Other Assets	23,356
Other Compr. Net Income	-13
Other Expenses	82,513
Other Liabilities	149,284
Other Net Income	-7,366
Other Revenues	107,672
Property and Equipment	22,160
Research and Development	107,506
Selling, General and Administrative Expense	37,437

Output Variable	Value in 1000 USD
Assets	250,951
Liabilities	237,379
Expenses	282,330
Revenues	107,672
Stockholders Equity	13,572
Net Income	-182,024
Comprehensive Net Income	-182,030
Economic Capital Ratio	-65%